KRAS and neoplasm: Now, upon metachronous dissemination of the tumor, a comprehensive TruSight Oncology 500 (TSO500) assay (Illumina, San Diego, USA), performed on a tumor specimen from the recent ileocecal resection, confirmed the initial KRAS p.G12C mutation and additionally identified an ANK3(Ex.28)::RET(Ex.2) fusion with breakpoints located at position chr10:61865663 and chr10:43595905, respectively (Fig. 2).